Reviewed listing: XETR:NBG6 · Analysis dated Oct 26, 2026
It has not been confirmed whether the basis of this analysis still holds today. Read it as a dated earlier assessment; it does not establish a current buying opportunity.
How does the company make money?
Nürnberger offers life, health, and property and casualty insurance. It earns primarily from insurance premiums and returns on invested money.
What supports the business?
Preliminary consolidated net income turned 2025 to 46.8 million euros, after a loss of 77 million euros in the prior year. This shows a significant recovery, but is not yet evidence of permanently higher earnings.
What could improve?
With VIG as its owner, Nürnberger could make greater use of its experience in life and biometric insurance across the group. This is a strategic possibility, but it guarantees neither higher earnings nor more than the stipulated compensation.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
122.50 euros is expensive: The fixed cash compensation is 120 euros per share, or 2.50 euros less. A good company is not worth any price; a possible later increase awarded by a court is not certain.
What is the main risk?
The announced transfer of the remaining shares is not yet effective; it requires a shareholders' meeting resolution and registration in the commercial register. Delays or a court review of the compensation can affect the payment and its value.
What is the overall assessment?
The earnings turnaround and support from VIG are positive. At the specified price, however, the stock price exceeds the established settlement amount; a higher amount later is uncertain. Therefore, the balance of business, price, and risk is unconvincing.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign in